Please ensure Javascript is enabled for purposes of website accessibility
Contact us Contact Us
EN
Home > Research Area > Neuroscience > Schizophrenia

Schizophrenia Research Reagents

Schizophrenia is a severe neuropsychiatric disorder affecting approximately 1% of the population, characterized by positive symptoms (hallucinations, delusions), negative symptoms (anhedonia, social withdrawal), and cognitive deficits. Pathophysiology involves dopaminergic hyperactivity in mesolimbic pathways, NMDA receptor hypofunction, and synaptic pruning abnormalities mediated by complement pathway dysregulation.

Research Use Only (RUO)Not intended for diagnostic or therapeutic procedures.

Schizophrenia Research Reagents - key pathogenic pathways and research targets

Fig. 1 Key pathogenic pathways and research targets. abinScience product targets highlighted in orange.

abinScience provides validated antibodies, recombinant proteins, and ELISA kits for key schizophrenia research targets. All products are manufactured by our parent company AtaGenix Laboratories under ISO quality systems. Browse products below or contact us for custom antibody development.

Key Research Targets

Dopamine Receptor D2 (DRD2) — DRD2 is the primary target of all approved antipsychotics. Anti-DRD2 antibodies support receptor density quantification, occupancy studies, and post-mortem brain tissue analysis in schizophrenia research.

NMDA Receptor (GRIN1/GRIN2A/GRIN2B) — NMDA receptor hypofunction is central to the glutamate hypothesis of schizophrenia. Anti-NMDA receptor subunit antibodies enable synaptic expression studies and glutamatergic signaling research.
→ Browse NMDA receptor antibodies

NRG1/ErbB4 — Neuregulin-1 (NRG1) signaling through ErbB4 regulates synaptic plasticity and myelination. NRG1 is a schizophrenia susceptibility gene. Anti-NRG1 and anti-ErbB4 antibodies support synaptic signaling studies.
→ Browse NRG1/ErbB4 antibodies & proteins

References

1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86-97. DOI

2. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III. Schizophr Bull. 2009;35(3):549-562. DOI

3. Sekar A, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177-183. DOI

4. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9(6):437-452. DOI

24 product results for "Schizophrenia"

Options+
Options
Confirm

Quick access

Contact Us

  • +86-27-65523339

  • [email protected]

  • Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China

  • linkedin
  • Ins
  • youtube
  • youtube
Copyright © 2026 abinScience. All Rights Reserved. All Products are for Research Use Only